Inhibitor Therapeutics, Inc.
INTI
$0.08
$0.0110.26%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.95% | -6.52% | -5.05% | -13.56% | -6.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.31% | 4.33% | 8.11% | 0.20% | 7.41% |
| Operating Income | 6.31% | -4.33% | -8.11% | -0.20% | -7.41% |
| Income Before Tax | 1.16% | -11.09% | -14.15% | -3.66% | -10.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.16% | -11.09% | -14.15% | -3.66% | -10.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.16% | -11.09% | -14.15% | -3.66% | -10.34% |
| EBIT | 6.31% | -4.33% | -8.11% | -0.20% | -7.41% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 1.55% | -11.17% | -13.64% | -3.24% | -10.23% |
| Normalized Basic EPS | 1.64% | -11.61% | -15.60% | -4.35% | -10.91% |
| EPS Diluted | 1.55% | -11.17% | -13.64% | -3.24% | -10.23% |
| Normalized Diluted EPS | 1.64% | -11.61% | -15.60% | -4.35% | -10.91% |
| Average Basic Shares Outstanding | 0.14% | 0.15% | 0.16% | 0.18% | 0.18% |
| Average Diluted Shares Outstanding | 0.14% | 0.15% | 0.16% | 0.18% | 0.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |